13 September 2022 | Tuesday | News
Beijing E-town Bio Park is located in Beijing Economic and Technological Development Zone and has attracted close to 200 prestigious life science enterprises from sectors including new drug R&D, diagnostic reagents, clinical testing, medical device, technical services and supporting services.
The signing ceremony took place at the 9th Beijing E-town (Beijing-Tianjin-Hebei Province) Biomedical Industry Conference and the 1st China Pharmaceutical Industry Innovation and Development Summit, which was co-hosted by the Beijing E-town Bio Park and Pharmaceutical and Chemical Industry Committee of China Chemical Enterprise Management Association.
This collaboration will extend to all of the service platforms managed, operated or established by Beijing E-town, including construction of the platform. Both parties will utilise the platform to provide a complete support service for the Beijing Economic and Technological Development Zone, and biomedical innovation research and development enterprises in Beijing.
Ting Xiao, Co-Head of DLA Piper’s China Life Sciences practice, and a Partner of the firm’s IP and Technology group, along with Asher Yan, Senior Consultant within the same group, represented DLA Piper at the signing ceremony.
Commenting on this strategic collaboration at the signing ceremony, Ting explains that “as one of the largest law firms in the world, DLA Piper is well-versed in IP protection, regulatory, compliance, M&A and other sectors related to the innovative life sciences industry. We are committed to helping Chinese enterprises within the park who want to explore opportunities outside of China”.
DLA Piper's global Life Sciences team consists of more than 350 lawyers across 40 jurisdictions who are experienced specialists with deep practical knowledge of the sector. Its lawyers advise clients in the pharmaceutical, medical device, biotechnology, R&D and diagnostics areas across a wide range of legal services including IP strategy and enforcement, M&A, dispute resolution, compliance and investigations.